Proactiveinvestors United Kingdom AstraZeneca https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom AstraZeneca RSS feed en Tue, 12 Nov 2019 08:00:32 +0000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) AstraZeneca anaemia drug data points to “yet another blockbuster” https://www.proactiveinvestors.co.uk/companies/news/906737/astrazeneca-anaemia-drug-data-points-to-yet-another-blockbuster-906737.html Mon, 11 Nov 2019 09:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/906737/astrazeneca-anaemia-drug-data-points-to-yet-another-blockbuster-906737.html AstraZeneca to release data likely to move anaemia drug’s sales value by US$3.7bn, analysts say https://www.proactiveinvestors.co.uk/companies/news/906634/astrazeneca-to-release-data-likely-to-move-anaemia-drugs-sales-value-by-us37bn-analysts-say-906634.html Fri, 08 Nov 2019 10:36:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/906634/astrazeneca-to-release-data-likely-to-move-anaemia-drugs-sales-value-by-us37bn-analysts-say-906634.html AstraZeneca to add $13bn product sales in next 5 years, says broker Liberum https://www.proactiveinvestors.co.uk/companies/news/905652/astrazeneca-to-add-13bn-product-sales-in-next-5-years-says-broker-liberum-905652.html Fri, 25 Oct 2019 12:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/905652/astrazeneca-to-add-13bn-product-sales-in-next-5-years-says-broker-liberum-905652.html FTSE 100 closes higher, bolstered by Aveva and AstraZeneca; Boris Johnson to seek December general election https://www.proactiveinvestors.co.uk/companies/news/905508/ftse-100-closes-higher-bolstered-by-aveva-and-astrazeneca-boris-johnson-to-seek-december-general-election-905508.html Thu, 24 Oct 2019 16:26:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/905508/ftse-100-closes-higher-bolstered-by-aveva-and-astrazeneca-boris-johnson-to-seek-december-general-election-905508.html AstraZeneca hikes sales target after new drug successes https://www.proactiveinvestors.co.uk/companies/news/905517/astrazeneca-hikes-sales-target-after-new-drug-successes-905517.html Thu, 24 Oct 2019 06:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/905517/astrazeneca-hikes-sales-target-after-new-drug-successes-905517.html AstraZeneca likely to remain in favour, banks update on PPI https://www.proactiveinvestors.co.uk/companies/news/905159/astrazeneca-likely-to-remain-in-favour-banks-update-on-ppi-905159.html Mon, 21 Oct 2019 05:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/905159/astrazeneca-likely-to-remain-in-favour-banks-update-on-ppi-905159.html FDA grants “priority review” status to AstraZeneca’s breast cancer antibody https://www.proactiveinvestors.co.uk/companies/news/905040/fda-grants-priority-review-status-to-astrazenecas-breast-cancer-antibody-905040.html Thu, 17 Oct 2019 08:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/905040/fda-grants-priority-review-status-to-astrazenecas-breast-cancer-antibody-905040.html AstraZeneca gets US clearance for asthma pen https://www.proactiveinvestors.co.uk/companies/news/904176/astrazeneca-gets-us-clearance-for-asthma-pen-904176.html Fri, 04 Oct 2019 09:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/904176/astrazeneca-gets-us-clearance-for-asthma-pen-904176.html IPO Roundup: Several biotech companies set to go public this week; WeWork cancels its IPO filing https://www.proactiveinvestors.co.uk/companies/news/903816/ipo-roundup-several-biotech-companies-set-to-go-public-this-week-wework-cancels-its-ipo-filing-903816.html Mon, 30 Sep 2019 16:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/903816/ipo-roundup-several-biotech-companies-set-to-go-public-this-week-wework-cancels-its-ipo-filing-903816.html Glaxo and AstraZeneca vie for position with "unprecedented" ovarian cancer trials https://www.proactiveinvestors.co.uk/companies/news/903775/glaxo-and-astrazeneca-vie-for-position-with--unprecedented--ovarian-cancer-trials-903775.html Mon, 30 Sep 2019 12:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/903775/glaxo-and-astrazeneca-vie-for-position-with--unprecedented--ovarian-cancer-trials-903775.html AstraZeneca shares hit all-time highs as it adds colour to recent trial data https://www.proactiveinvestors.co.uk/companies/news/901854/astrazeneca-shares-hit-all-time-highs-as-it-adds-colour-to-recent-trial-data-901854.html Mon, 02 Sep 2019 08:28:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/901854/astrazeneca-shares-hit-all-time-highs-as-it-adds-colour-to-recent-trial-data-901854.html AstraZeneca scores another late-stage win, this time with COPD drug https://www.proactiveinvestors.co.uk/companies/news/901623/astrazeneca-scores-another-late-stage-win-this-time-with-copd-drug-901623.html Wed, 28 Aug 2019 08:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/901623/astrazeneca-scores-another-late-stage-win-this-time-with-copd-drug-901623.html Amryt Pharma: The AIM drug developer potentially sitting on a US$100mln piece of paper https://www.proactiveinvestors.co.uk/companies/news/901340/amryt-pharma-the-aim-drug-developer-potentially-sitting-on-a-us100mln-piece-of-paper-901340.html Thu, 22 Aug 2019 14:09:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/901340/amryt-pharma-the-aim-drug-developer-potentially-sitting-on-a-us100mln-piece-of-paper-901340.html AstraZeneca scores another regulatory win in China for roxadustat anaemia drug https://www.proactiveinvestors.co.uk/companies/news/901301/astrazeneca-scores-another-regulatory-win-in-china-for-roxadustat-anaemia-drug-901301.html Thu, 22 Aug 2019 07:55:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/901301/astrazeneca-scores-another-regulatory-win-in-china-for-roxadustat-anaemia-drug-901301.html AstraZeneca’s cancer drug combo stumbles in phase III lung cancer trial https://www.proactiveinvestors.co.uk/companies/news/901207/astrazenecas-cancer-drug-combo-stumbles-in-phase-iii-lung-cancer-trial-901207.html Wed, 21 Aug 2019 06:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/901207/astrazenecas-cancer-drug-combo-stumbles-in-phase-iii-lung-cancer-trial-901207.html AstraZeneca nears £100bn market cap as remarkable drug pipeline turnaround continues https://www.proactiveinvestors.co.uk/companies/news/901158/astrazeneca-nears-100bn-market-cap-as-remarkable-drug-pipeline-turnaround-continues-901158.html Tue, 20 Aug 2019 14:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/901158/astrazeneca-nears-100bn-market-cap-as-remarkable-drug-pipeline-turnaround-continues-901158.html AstraZeneca pumps higher as Farxiga shows benefit in late-stage heart-failure study https://www.proactiveinvestors.co.uk/companies/news/901120/astrazeneca-pumps-higher-as-farxiga-shows-benefit-in-late-stage-heart-failure-study-901120.html Tue, 20 Aug 2019 08:38:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/901120/astrazeneca-pumps-higher-as-farxiga-shows-benefit-in-late-stage-heart-failure-study-901120.html AstraZeneca’s Lynparza meets primary endpoint in late-stage ovarian cancer trial https://www.proactiveinvestors.co.uk/companies/news/900745/astrazenecas-lynparza-meets-primary-endpoint-in-late-stage-ovarian-cancer-trial-900745.html Wed, 14 Aug 2019 11:58:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/900745/astrazenecas-lynparza-meets-primary-endpoint-in-late-stage-ovarian-cancer-trial-900745.html AstraZeneca’s market value swells by £4bn after forecast-busting second-quarter results https://www.proactiveinvestors.co.uk/companies/news/224482/astrazenecas-market-value-swells-by-4bn-after-forecast-busting-second-quarter-results-224482.html Thu, 25 Jul 2019 07:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/224482/astrazenecas-market-value-swells-by-4bn-after-forecast-busting-second-quarter-results-224482.html US regulators grant orphan drug status to AstraZeneca’s Imfinzi cancer drug https://www.proactiveinvestors.co.uk/companies/news/223812/us-regulators-grant-orphan-drug-status-to-astrazenecas-imfinzi-cancer-drug-223812.html Fri, 12 Jul 2019 07:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/223812/us-regulators-grant-orphan-drug-status-to-astrazenecas-imfinzi-cancer-drug-223812.html AstraZeneca gets two positive opinions from European Medicines Agency committee https://www.proactiveinvestors.co.uk/companies/news/223127/astrazeneca-gets-two-positive-opinions-from-european-medicines-agency-committee-223127.html Mon, 01 Jul 2019 08:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/223127/astrazeneca-gets-two-positive-opinions-from-european-medicines-agency-committee-223127.html AstraZeneca gets EU approval for Lynparza as ovarian cancer treatment https://www.proactiveinvestors.co.uk/companies/news/222317/astrazeneca-gets-eu-approval-for-lynparza-as-ovarian-cancer-treatment-222317.html Tue, 18 Jun 2019 08:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/222317/astrazeneca-gets-eu-approval-for-lynparza-as-ovarian-cancer-treatment-222317.html AstraZeneca sees further encouraging effects from leukaemia treatment Calquence https://www.proactiveinvestors.co.uk/companies/news/222223/astrazeneca-sees-further-encouraging-effects-from-leukaemia-treatment-calquence-222223.html Mon, 17 Jun 2019 08:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/222223/astrazeneca-sees-further-encouraging-effects-from-leukaemia-treatment-calquence-222223.html AstraZeneca drug for chronic lymphocytic leukaemia successfully navigates phase III trial https://www.proactiveinvestors.co.uk/companies/news/221615/astrazeneca-drug-for-chronic-lymphocytic-leukaemia-successfully-navigates-phase-iii-trial-221615.html Thu, 06 Jun 2019 12:10:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221615/astrazeneca-drug-for-chronic-lymphocytic-leukaemia-successfully-navigates-phase-iii-trial-221615.html AstraZeneca reports positive results from trial of pancreatic cancer treatment https://www.proactiveinvestors.co.uk/companies/news/221371/astrazeneca-reports-positive-results-from-trial-of-pancreatic-cancer-treatment-221371.html Mon, 03 Jun 2019 07:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221371/astrazeneca-reports-positive-results-from-trial-of-pancreatic-cancer-treatment-221371.html AstraZeneca gets US regulatory green light for slow-release diabetes drug https://www.proactiveinvestors.co.uk/companies/news/219634/astrazeneca-gets-us-regulatory-green-light-for-slow-release-diabetes-drug-219634.html Fri, 03 May 2019 06:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219634/astrazeneca-gets-us-regulatory-green-light-for-slow-release-diabetes-drug-219634.html AstraZeneca’s Lynparza set for EU approval as advanced ovarian cancer maintenance treatment https://www.proactiveinvestors.co.uk/companies/news/219244/astrazenecas-lynparza-set-for-eu-approval-as-advanced-ovarian-cancer-maintenance-treatment-219244.html Mon, 29 Apr 2019 13:55:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219244/astrazenecas-lynparza-set-for-eu-approval-as-advanced-ovarian-cancer-maintenance-treatment-219244.html AstraZeneca first-quarter profits double as product sales revival continues but cash still a worry https://www.proactiveinvestors.co.uk/companies/news/219154/astrazeneca-first-quarter-profits-double-as-product-sales-revival-continues-but-cash-still-a-worry-219154.html Fri, 26 Apr 2019 06:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219154/astrazeneca-first-quarter-profits-double-as-product-sales-revival-continues-but-cash-still-a-worry-219154.html AstraZeneca’s new Japanese cancer drug tipped to rack up billions in annual sales https://www.proactiveinvestors.co.uk/companies/news/218047/astrazenecas-new-japanese-cancer-drug-tipped-to-rack-up-billions-in-annual-sales-218047.html Fri, 05 Apr 2019 08:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218047/astrazenecas-new-japanese-cancer-drug-tipped-to-rack-up-billions-in-annual-sales-218047.html AstraZeneca is still not converting top-line momentum into cash-flow, says UBS https://www.proactiveinvestors.co.uk/companies/news/217751/astrazeneca-is-still-not-converting-top-line-momentum-into-cash-flow-says-ubs-217751.html Tue, 02 Apr 2019 09:37:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217751/astrazeneca-is-still-not-converting-top-line-momentum-into-cash-flow-says-ubs-217751.html AstraZeneca granted Breakthrough Therapy Designation for rare genetic condition treatment https://www.proactiveinvestors.co.uk/companies/news/217611/astrazeneca-granted-breakthrough-therapy-designation-for-rare-genetic-condition-treatment-217611.html Mon, 01 Apr 2019 06:57:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217611/astrazeneca-granted-breakthrough-therapy-designation-for-rare-genetic-condition-treatment-217611.html AstraZeneca launches UK's biggest cash call this year to fund £5.2bn Japanese cancer deal https://www.proactiveinvestors.co.uk/companies/news/217496/astrazeneca-launches-uk-s-biggest-cash-call-this-year-to-fund-52bn-japanese-cancer-deal-217496.html Fri, 29 Mar 2019 11:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/217496/astrazeneca-launches-uk-s-biggest-cash-call-this-year-to-fund-52bn-japanese-cancer-deal-217496.html AstraZeneca wins regulatory approval for Europe's first type-1 diabetes drug taken by mouth https://www.proactiveinvestors.co.uk/companies/news/217090/astrazeneca-wins-regulatory-approval-for-europe-s-first-type-1-diabetes-drug-taken-by-mouth-217090.html Mon, 25 Mar 2019 07:56:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/217090/astrazeneca-wins-regulatory-approval-for-europe-s-first-type-1-diabetes-drug-taken-by-mouth-217090.html AstraZeneca reports pancreatic cancer trial success for Lynparza https://www.proactiveinvestors.co.uk/companies/news/215294/astrazeneca-reports-pancreatic-cancer-trial-success-for-lynparza-215294.html Tue, 26 Feb 2019 07:54:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215294/astrazeneca-reports-pancreatic-cancer-trial-success-for-lynparza-215294.html AstraZeneca rises as Brilinta medicine meets goal in Phase III clinical trial https://www.proactiveinvestors.co.uk/companies/news/215236/astrazeneca-rises-as-brilinta-medicine-meets-goal-in-phase-iii-clinical-trial-215236.html Mon, 25 Feb 2019 13:53:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215236/astrazeneca-rises-as-brilinta-medicine-meets-goal-in-phase-iii-clinical-trial-215236.html AstraZeneca posts first rise in annual product sales for almost ten years https://www.proactiveinvestors.co.uk/companies/news/214621/astrazeneca-posts-first-rise-in-annual-product-sales-for-almost-ten-years-214621.html Thu, 14 Feb 2019 12:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214621/astrazeneca-posts-first-rise-in-annual-product-sales-for-almost-ten-years-214621.html Double boost from European and US regulators for AstraZeneca’s lung infection treatment https://www.proactiveinvestors.co.uk/companies/news/213967/double-boost-from-european-and-us-regulators-for-astrazenecas-lung-infection-treatment-213967.html Tue, 05 Feb 2019 08:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/213967/double-boost-from-european-and-us-regulators-for-astrazenecas-lung-infection-treatment-213967.html AstraZeneca appoints leading cancer researcher José Baselga as new head of oncology R&D https://www.proactiveinvestors.co.uk/companies/news/212074/astrazeneca-appoints-leading-cancer-researcher-jos-baselga-as-new-head-of-oncology-rd-212074.html Mon, 07 Jan 2019 14:43:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212074/astrazeneca-appoints-leading-cancer-researcher-jos-baselga-as-new-head-of-oncology-rd-212074.html Hat-trick for AstraZeneca as its cancer and anaemia drugs come up trumps in three late-stage trials https://www.proactiveinvestors.co.uk/companies/news/211555/hat-trick-for-astrazeneca-as-its-cancer-and-anaemia-drugs-come-up-trumps-in-three-late-stage-trials-211555.html Thu, 20 Dec 2018 08:43:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211555/hat-trick-for-astrazeneca-as-its-cancer-and-anaemia-drugs-come-up-trumps-in-three-late-stage-trials-211555.html AstraZeneca partner gets approval to market its roxadustat drug as an anaemia treatment in China https://www.proactiveinvestors.co.uk/companies/news/211404/astrazeneca-partner-gets-approval-to-market-its-roxadustat-drug-as-an-anaemia-treatment-in-china-211404.html Tue, 18 Dec 2018 11:59:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211404/astrazeneca-partner-gets-approval-to-market-its-roxadustat-drug-as-an-anaemia-treatment-in-china-211404.html AstraZeneca’s Imfinzi cancer drug fails in another late-stage trial https://www.proactiveinvestors.co.uk/companies/news/210755/astrazenecas-imfinzi-cancer-drug-fails-in-another-late-stage-trial-210755.html Fri, 07 Dec 2018 08:10:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210755/astrazenecas-imfinzi-cancer-drug-fails-in-another-late-stage-trial-210755.html AstraZeneca PLC wins Orphan Drug Designation for Fasenra to treat rare autoimmune disease https://www.proactiveinvestors.co.uk/companies/news/209891/astrazeneca-plc-wins-orphan-drug-designation-for-fasenra-to-treat-rare-autoimmune-disease-209891.html Mon, 26 Nov 2018 07:38:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/209891/astrazeneca-plc-wins-orphan-drug-designation-for-fasenra-to-treat-rare-autoimmune-disease-209891.html AstraZeneca in cancer drug setback https://www.proactiveinvestors.co.uk/companies/news/209343/astrazeneca-in-cancer-drug-setback-209343.html Fri, 16 Nov 2018 07:22:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/209343/astrazeneca-in-cancer-drug-setback-209343.html AstraZeneca sells off US rights to children’s lung disease treatment for up to US$2bn https://www.proactiveinvestors.co.uk/companies/news/209066/astrazeneca-sells-off-us-rights-to-childrens-lung-disease-treatment-for-up-to-us2bn-209066.html Tue, 13 Nov 2018 07:50:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/209066/astrazeneca-sells-off-us-rights-to-childrens-lung-disease-treatment-for-up-to-us2bn-209066.html AstraZeneca serves up a double dose of good news https://www.proactiveinvestors.co.uk/companies/news/208990/astrazeneca-serves-up-a-double-dose-of-good-news-208990.html Mon, 12 Nov 2018 08:04:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208990/astrazeneca-serves-up-a-double-dose-of-good-news-208990.html AstraZeneca confirms full-year guidance; CEO says results mark an important milestone https://www.proactiveinvestors.co.uk/companies/news/208804/astrazeneca-confirms-full-year-guidance-ceo-says-results-mark-an-important-milestone-208804.html Thu, 08 Nov 2018 07:52:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208804/astrazeneca-confirms-full-year-guidance-ceo-says-results-mark-an-important-milestone-208804.html AstraZeneca sells off three more non-core drugs for US$370mln https://www.proactiveinvestors.co.uk/companies/news/208609/astrazeneca-sells-off-three-more-non-core-drugs-for-us370mln-208609.html Tue, 06 Nov 2018 10:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208609/astrazeneca-sells-off-three-more-non-core-drugs-for-us370mln-208609.html AstraZeneca sells rights to two of its ‘non-core’ drugs for almost US$1bn https://www.proactiveinvestors.co.uk/companies/news/208099/astrazeneca-sells-rights-to-two-of-its-non-core-drugs-for-almost-us1bn-208099.html Tue, 30 Oct 2018 08:24:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208099/astrazeneca-sells-rights-to-two-of-its-non-core-drugs-for-almost-us1bn-208099.html AstraZeneca reveals trial of Lynparza drug reduces risk of ovarian cancer worsening https://www.proactiveinvestors.co.uk/companies/news/207540/astrazeneca-reveals-trial-of-lynparza-drug-reduces-risk-of-ovarian-cancer-worsening-207540.html Mon, 22 Oct 2018 07:33:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207540/astrazeneca-reveals-trial-of-lynparza-drug-reduces-risk-of-ovarian-cancer-worsening-207540.html AstraZeneca’s Lynparza given orphan drug status for treatment of pancreatic cancer https://www.proactiveinvestors.co.uk/companies/news/207162/astrazenecas-lynparza-given-orphan-drug-status-for-treatment-of-pancreatic-cancer-207162.html Tue, 16 Oct 2018 07:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207162/astrazenecas-lynparza-given-orphan-drug-status-for-treatment-of-pancreatic-cancer-207162.html AstraZeneca drug successfully negotiates final-stage clinical trial https://www.proactiveinvestors.co.uk/companies/news/205503/astrazeneca-drug-successfully-negotiates-final-stage-clinical-trial-205503.html Mon, 24 Sep 2018 06:43:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205503/astrazeneca-drug-successfully-negotiates-final-stage-clinical-trial-205503.html AstraZeneca leukaemia drug receives US regulatory green light https://www.proactiveinvestors.co.uk/companies/news/204896/astrazeneca-leukaemia-drug-receives-us-regulatory-green-light-204896.html Fri, 14 Sep 2018 06:26:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204896/astrazeneca-leukaemia-drug-receives-us-regulatory-green-light-204896.html AstraZeneca’s severe asthma treatment granted breakthrough therapy designation https://www.proactiveinvestors.co.uk/companies/news/204419/astrazenecas-severe-asthma-treatment-granted-breakthrough-therapy-designation-204419.html Fri, 07 Sep 2018 07:38:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204419/astrazenecas-severe-asthma-treatment-granted-breakthrough-therapy-designation-204419.html AstraZeneca’s lupus drug falls at final hurdle https://www.proactiveinvestors.co.uk/companies/news/203954/astrazenecas-lupus-drug-falls-at-final-hurdle-203954.html Fri, 31 Aug 2018 07:11:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/203954/astrazenecas-lupus-drug-falls-at-final-hurdle-203954.html AstraZeneca’s new diabetes autoinjector pen approved by European regulators https://www.proactiveinvestors.co.uk/companies/news/203861/astrazenecas-new-diabetes-autoinjector-pen-approved-by-european-regulators-203861.html Thu, 30 Aug 2018 07:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/203861/astrazenecas-new-diabetes-autoinjector-pen-approved-by-european-regulators-203861.html AstraZeneca valuation 'too stretched', says Jefferies as it downgrades the stock https://www.proactiveinvestors.co.uk/companies/news/203054/astrazeneca-valuation-too-stretched-says-jefferies-as-it-downgrades-the-stock-203054.html Thu, 16 Aug 2018 10:38:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/203054/astrazeneca-valuation-too-stretched-says-jefferies-as-it-downgrades-the-stock-203054.html JPMorgan Cazenove gives AstraZeneca shares a boost, hiking its target price to 6,500p from 5,800p https://www.proactiveinvestors.co.uk/companies/news/202593/jpmorgan-cazenove-gives-astrazeneca-shares-a-boost-hiking-its-target-price-to-6500p-from-5800p-202593.html Thu, 09 Aug 2018 13:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/202593/jpmorgan-cazenove-gives-astrazeneca-shares-a-boost-hiking-its-target-price-to-6500p-from-5800p-202593.html AstraZeneca plots a return to growth as cancer portfolio boosts first-half performance https://www.proactiveinvestors.co.uk/companies/news/201620/astrazeneca-plots-a-return-to-growth-as-cancer-portfolio-boosts-first-half-performance-201620.html Thu, 26 Jul 2018 11:10:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/201620/astrazeneca-plots-a-return-to-growth-as-cancer-portfolio-boosts-first-half-performance-201620.html AstraZeneca sells European rights to heart drug https://www.proactiveinvestors.co.uk/companies/news/201410/astrazeneca-sells-european-rights-to-heart-drug-201410.html Tue, 24 Jul 2018 07:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/201410/astrazeneca-sells-european-rights-to-heart-drug-201410.html Two of AstraZeneca’s key cancer drugs win speedy approvals in Japan https://www.proactiveinvestors.co.uk/companies/news/199949/two-of-astrazenecas-key-cancer-drugs-win-speedy-approvals-in-japan-199949.html Mon, 02 Jul 2018 09:48:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/199949/two-of-astrazenecas-key-cancer-drugs-win-speedy-approvals-in-japan-199949.html AstraZeneca’s Lynparza drug sails through late-stage ovarian cancer study https://www.proactiveinvestors.co.uk/companies/news/199658/astrazenecas-lynparza-drug-sails-through-late-stage-ovarian-cancer-study-199658.html Wed, 27 Jun 2018 08:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/199658/astrazenecas-lynparza-drug-sails-through-late-stage-ovarian-cancer-study-199658.html UBS reckons Tagrisso will be worth more than US$5bn a year to AstraZeneca by 2022 https://www.proactiveinvestors.co.uk/companies/news/199490/ubs-reckons-tagrisso-will-be-worth-more-than-us5bn-a-year-to-astrazeneca-by-2022-199490.html Mon, 25 Jun 2018 10:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/199490/ubs-reckons-tagrisso-will-be-worth-more-than-us5bn-a-year-to-astrazeneca-by-2022-199490.html AstraZeneca’s pipeline turnaround is “remarkable”, but potential is already priced in https://www.proactiveinvestors.co.uk/companies/news/199222/astrazenecas-pipeline-turnaround-is-remarkable-but-potential-is-already-priced-in-199222.html Wed, 20 Jun 2018 10:48:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/199222/astrazenecas-pipeline-turnaround-is-remarkable-but-potential-is-already-priced-in-199222.html AstraZeneca and Eli Lilly halt late-stage Alzheimer’s study as drug shows no sign of working https://www.proactiveinvestors.co.uk/companies/news/198668/astrazeneca-and-eli-lilly-halt-late-stage-alzheimers-study-as-drug-shows-no-sign-of-working-198668.html Tue, 12 Jun 2018 12:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/198668/astrazeneca-and-eli-lilly-halt-late-stage-alzheimers-study-as-drug-shows-no-sign-of-working-198668.html AstraZeneca and Merck present data from prostate cancer trial at ASCO 2018 https://www.proactiveinvestors.co.uk/companies/news/198278/astrazeneca-and-merck-present-data-from-prostate-cancer-trial-at-asco-2018-198278.html Tue, 05 Jun 2018 11:41:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/198278/astrazeneca-and-merck-present-data-from-prostate-cancer-trial-at-asco-2018-198278.html AstraZeneca chalks up another phase III fail as COPD drug misses target https://www.proactiveinvestors.co.uk/companies/news/197899/astrazeneca-chalks-up-another-phase-iii-fail-as-copd-drug-misses-target-197899.html Wed, 30 May 2018 07:08:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197899/astrazeneca-chalks-up-another-phase-iii-fail-as-copd-drug-misses-target-197899.html AstraZeneca receives more solid data for its Imfinzi lung cancer treatment https://www.proactiveinvestors.co.uk/companies/news/197696/astrazeneca-receives-more-solid-data-for-its-imfinzi-lung-cancer-treatment-197696.html Fri, 25 May 2018 07:09:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197696/astrazeneca-receives-more-solid-data-for-its-imfinzi-lung-cancer-treatment-197696.html Third time lucky for AstraZeneca and its Lokelma hyperkalaemia treatment https://www.proactiveinvestors.co.uk/companies/news/197354/third-time-lucky-for-astrazeneca-and-its-lokelma-hyperkalaemia-treatment-197354.html Mon, 21 May 2018 07:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197354/third-time-lucky-for-astrazeneca-and-its-lokelma-hyperkalaemia-treatment-197354.html AstraZeneca disappoints with Q1 sales but ‘remains on track’ to hit full-year growth guidance https://www.proactiveinvestors.co.uk/companies/news/197253/astrazeneca-disappoints-with-q1-sales-but-remains-on-track-to-hit-full-year-growth-guidance-197253.html Fri, 18 May 2018 10:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197253/astrazeneca-disappoints-with-q1-sales-but-remains-on-track-to-hit-full-year-growth-guidance-197253.html AstraZeneca suffers clinical setback https://www.proactiveinvestors.co.uk/companies/news/196808/astrazeneca-suffers-clinical-setback-196808.html Fri, 11 May 2018 06:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/196808/astrazeneca-suffers-clinical-setback-196808.html AstraZeneca sells off rights to Seroquel for US$538mln https://www.proactiveinvestors.co.uk/companies/news/196537/astrazeneca-sells-off-rights-to-seroquel-for-us538mln-196537.html Tue, 08 May 2018 07:47:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/196537/astrazeneca-sells-off-rights-to-seroquel-for-us538mln-196537.html AstraZeneca shares under pressure after lung cancer setback https://www.proactiveinvestors.co.uk/companies/news/195638/astrazeneca-shares-under-pressure-after-lung-cancer-setback-195638.html Tue, 24 Apr 2018 07:13:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195638/astrazeneca-shares-under-pressure-after-lung-cancer-setback-195638.html US FDA approves AstraZenca’s Tagrisso drug as first-line treatment for lung cancer https://www.proactiveinvestors.co.uk/companies/news/195346/us-fda-approves-astrazencas-tagrisso-drug-as-first-line-treatment-for-lung-cancer-195346.html Thu, 19 Apr 2018 07:52:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195346/us-fda-approves-astrazencas-tagrisso-drug-as-first-line-treatment-for-lung-cancer-195346.html AstraZeneca and GlaxoSmithKline share price targets tweaked and on Jefferies' 'buy' ahead of Q1 results season for the druggies https://www.proactiveinvestors.co.uk/companies/news/194947/astrazeneca-and-glaxosmithkline-share-price-targets-tweaked-and-on-jefferies-buy-ahead-of-q1-results-season-for-the-druggies-194947.html Fri, 13 Apr 2018 11:08:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/194947/astrazeneca-and-glaxosmithkline-share-price-targets-tweaked-and-on-jefferies-buy-ahead-of-q1-results-season-for-the-druggies-194947.html US and European regulators accept AstraZeneca's cancer drug applications https://www.proactiveinvestors.co.uk/companies/news/194130/us-and-european-regulators-accept-astrazeneca-s-cancer-drug-applications-194130.html Tue, 03 Apr 2018 07:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/194130/us-and-european-regulators-accept-astrazeneca-s-cancer-drug-applications-194130.html Jefferies upgrades AstraZeneca rating to ‘buy’ from ‘hold’ as it believes drugmaker “is at a turning point” https://www.proactiveinvestors.co.uk/companies/news/193377/jefferies-upgrades-astrazeneca-rating-to-buy-from-hold-as-it-believes-drugmaker-is-at-a-turning-point-193377.html Mon, 19 Mar 2018 10:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/193377/jefferies-upgrades-astrazeneca-rating-to-buy-from-hold-as-it-believes-drugmaker-is-at-a-turning-point-193377.html AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial https://www.proactiveinvestors.co.uk/companies/news/192968/astrazeneca-pushes-back-timeline-for-mystic-phase-iii-lung-cancer-clinical-trial-192968.html Mon, 12 Mar 2018 07:29:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/192968/astrazeneca-pushes-back-timeline-for-mystic-phase-iii-lung-cancer-clinical-trial-192968.html AstraZeneca: Trump tax bump can't disguise the challenge it and other druggies face https://www.proactiveinvestors.co.uk/companies/news/191051/astrazeneca-trump-tax-bump-can-t-disguise-the-challenge-it-and-other-druggies-face-191051.html Fri, 02 Feb 2018 13:17:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/191051/astrazeneca-trump-tax-bump-can-t-disguise-the-challenge-it-and-other-druggies-face-191051.html AstraZeneca reports positive top-line data from phase III COPD trial https://www.proactiveinvestors.co.uk/companies/news/190671/astrazeneca-reports-positive-top-line-data-from-phase-iii-copd-trial-190671.html Fri, 26 Jan 2018 07:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/190671/astrazeneca-reports-positive-top-line-data-from-phase-iii-copd-trial-190671.html AstraZeneca gets approval for two cancer and asthma treatments in Japan https://www.proactiveinvestors.co.uk/companies/news/190287/astrazeneca-gets-approval-for-two-cancer-and-asthma-treatments-in-japan-190287.html Fri, 19 Jan 2018 14:10:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/190287/astrazeneca-gets-approval-for-two-cancer-and-asthma-treatments-in-japan-190287.html Immuno-oncology: What does 2018 have in store for Big Pharma and their cancer immunotherapies? https://www.proactiveinvestors.co.uk/companies/news/189176/immuno-oncology-what-does-2018-have-in-store-for-big-pharma-and-their-cancer-immunotherapies-189176.html Wed, 27 Dec 2017 08:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/189176/immuno-oncology-what-does-2018-have-in-store-for-big-pharma-and-their-cancer-immunotherapies-189176.html AstraZeneca submits supplemental new drug application for Tagrisso in Japan https://www.proactiveinvestors.co.uk/companies/news/187806/astrazeneca-submits-supplemental-new-drug-application-for-tagrisso-in-japan-187806.html Mon, 27 Nov 2017 07:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/187806/astrazeneca-submits-supplemental-new-drug-application-for-tagrisso-in-japan-187806.html AstraZeneca shares up 1.2% after getting regulatory green light for asthma drug https://www.proactiveinvestors.co.uk/companies/news/187283/astrazeneca-shares-up-12-after-getting-regulatory-green-light-for-asthma-drug-187283.html Wed, 15 Nov 2017 08:22:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/187283/astrazeneca-shares-up-12-after-getting-regulatory-green-light-for-asthma-drug-187283.html AstraZeneca lifts full-year core earnings guidance https://www.proactiveinvestors.co.uk/companies/news/187004/astrazeneca-lifts-full-year-core-earnings-guidance-187004.html Thu, 09 Nov 2017 12:46:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/187004/astrazeneca-lifts-full-year-core-earnings-guidance-187004.html AstraZeneca’s severe asthma treatment fails in late-stage study but FDA approval of rare blood cancer drug boosts shares https://www.proactiveinvestors.co.uk/companies/news/186563/astrazenecas-severe-asthma-treatment-fails-in-late-stage-study-but-fda-approval-of-rare-blood-cancer-drug-boosts-shares-186563.html Wed, 01 Nov 2017 08:33:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/186563/astrazenecas-severe-asthma-treatment-fails-in-late-stage-study-but-fda-approval-of-rare-blood-cancer-drug-boosts-shares-186563.html AstraZeneca edges higher after double dose of updates on cancer and diabetes drugs https://www.proactiveinvestors.co.uk/companies/news/186012/astrazeneca-edges-higher-after-double-dose-of-updates-on-cancer-and-diabetes-drugs-186012.html Mon, 23 Oct 2017 07:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/186012/astrazeneca-edges-higher-after-double-dose-of-updates-on-cancer-and-diabetes-drugs-186012.html AstraZeneca’s breast cancer drug given priority review by FDA https://www.proactiveinvestors.co.uk/companies/news/185785/astrazenecas-breast-cancer-drug-given-priority-review-by-fda-185785.html Wed, 18 Oct 2017 13:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/185785/astrazenecas-breast-cancer-drug-given-priority-review-by-fda-185785.html AstraZeneca’s Imfinzi cancer drug clears another regulatory hurdle https://www.proactiveinvestors.co.uk/companies/news/185709/astrazenecas-imfinzi-cancer-drug-clears-another-regulatory-hurdle-185709.html Tue, 17 Oct 2017 09:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/185709/astrazenecas-imfinzi-cancer-drug-clears-another-regulatory-hurdle-185709.html AstraZeneca rises as Credit Suisse praises recent progress, hikes price target by £10 https://www.proactiveinvestors.co.uk/companies/news/185639/astrazeneca-rises-as-credit-suisse-praises-recent-progress-hikes-price-target-by-10-185639.html Mon, 16 Oct 2017 09:46:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/185639/astrazeneca-rises-as-credit-suisse-praises-recent-progress-hikes-price-target-by-10-185639.html AstraZeneca continues to face pricing pressures and competitive headwinds, says ShoreCap https://www.proactiveinvestors.co.uk/companies/news/185591/astrazeneca-continues-to-face-pricing-pressures-and-competitive-headwinds-says-shorecap-185591.html Fri, 13 Oct 2017 14:55:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/185591/astrazeneca-continues-to-face-pricing-pressures-and-competitive-headwinds-says-shorecap-185591.html AstraZeneca’s Tagrisso lung cancer drug granted ‘breakthrough therapy designation’ by US FDA https://www.proactiveinvestors.co.uk/companies/news/185252/astrazenecas-tagrisso-lung-cancer-drug-granted-breakthrough-therapy-designation-by-us-fda-185252.html Mon, 09 Oct 2017 11:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/185252/astrazenecas-tagrisso-lung-cancer-drug-granted-breakthrough-therapy-designation-by-us-fda-185252.html Exane BNP Paribas swoons over AstraZeneca’s drugs pipeline as it upgrades to 'outperform' https://www.proactiveinvestors.co.uk/companies/news/184593/exane-bnp-paribas-swoons-over-astrazenecas-drugs-pipeline-as-it-upgrades-to-outperform--184593.html Tue, 26 Sep 2017 14:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/184593/exane-bnp-paribas-swoons-over-astrazenecas-drugs-pipeline-as-it-upgrades-to-outperform--184593.html Bernstein ups stance on AstraZeneca to ‘outperform’, citing big pipeline, takeover possibilities https://www.proactiveinvestors.co.uk/companies/news/184436/bernstein-ups-stance-on-astrazeneca-to-outperform-citing-big-pipeline-takeover-possibilities-184436.html Fri, 22 Sep 2017 10:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/184436/bernstein-ups-stance-on-astrazeneca-to-outperform-citing-big-pipeline-takeover-possibilities-184436.html AstraZeneca offloads remaining rights to anaesthetic portfolio to Aspen for US$766mln https://www.proactiveinvestors.co.uk/companies/news/183980/astrazeneca-offloads-remaining-rights-to-anaesthetic-portfolio-to-aspen-for-us766mln-183980.html Thu, 14 Sep 2017 08:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/183980/astrazeneca-offloads-remaining-rights-to-anaesthetic-portfolio-to-aspen-for-us766mln-183980.html AstraZeneca lung cancer trial results impress but risks remain, analysts say https://www.proactiveinvestors.co.uk/companies/news/183753/astrazeneca-lung-cancer-trial-results-impress-but-risks-remain-analysts-say-183753.html Mon, 11 Sep 2017 14:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/183753/astrazeneca-lung-cancer-trial-results-impress-but-risks-remain-analysts-say-183753.html AstraZeneca gains after reporting positive results from two trials of lung cancer treatments https://www.proactiveinvestors.co.uk/companies/news/183731/astrazeneca-gains-after-reporting-positive-results-from-two-trials-of-lung-cancer-treatments-183731.html Mon, 11 Sep 2017 08:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/183731/astrazeneca-gains-after-reporting-positive-results-from-two-trials-of-lung-cancer-treatments-183731.html Natixis upgrades AstraZeneca to ‘buy’ on prospect of positive results from key MYSTIC lung cancer trial https://www.proactiveinvestors.co.uk/companies/news/183527/natixis-upgrades-astrazeneca-to-buy-on-prospect-of-positive-results-from-key-mystic-lung-cancer-trial-183527.html Wed, 06 Sep 2017 10:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/183527/natixis-upgrades-astrazeneca-to-buy-on-prospect-of-positive-results-from-key-mystic-lung-cancer-trial-183527.html AstraZeneca gets regulatory green light for breast cancer drug https://www.proactiveinvestors.co.uk/companies/news/183082/astrazeneca-gets-regulatory-green-light-for-breast-cancer-drug-183082.html Tue, 29 Aug 2017 07:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/183082/astrazeneca-gets-regulatory-green-light-for-breast-cancer-drug-183082.html Champions Oncology hooks up with AstraZeneca to work on characterising tumour models https://www.proactiveinvestors.co.uk/companies/news/182746/champions-oncology-hooks-up-with-astrazeneca-to-work-on-characterising-tumour-models-182746.html Mon, 21 Aug 2017 13:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/182746/champions-oncology-hooks-up-with-astrazeneca-to-work-on-characterising-tumour-models-182746.html AstraZeneca ovarian cancer drug approved for wider use https://www.proactiveinvestors.co.uk/companies/news/182652/astrazeneca-ovarian-cancer-drug-approved-for-wider-use-182652.html Fri, 18 Aug 2017 06:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/182652/astrazeneca-ovarian-cancer-drug-approved-for-wider-use-182652.html AstraZeneca scores much-needed clinical success https://www.proactiveinvestors.co.uk/companies/news/181834/astrazeneca-scores-much-needed-clinical-success-181834.html Wed, 02 Aug 2017 13:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/181834/astrazeneca-scores-much-needed-clinical-success-181834.html AstraZeneca bolstered by FDA news on lung cancer drug Imfinzi https://www.proactiveinvestors.co.uk/companies/news/181726/astrazeneca-bolstered-by-fda-news-on-lung-cancer-drug-imfinzi-181726.html Mon, 31 Jul 2017 14:46:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/181726/astrazeneca-bolstered-by-fda-news-on-lung-cancer-drug-imfinzi-181726.html AstraZeneca on the front foot after US FDA speeds up process for Imfinzi lung cancer drug https://www.proactiveinvestors.co.uk/companies/news/181697/astrazeneca-on-the-front-foot-after-us-fda-speeds-up-process-for-imfinzi-lung-cancer-drug-181697.html Mon, 31 Jul 2017 12:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/181697/astrazeneca-on-the-front-foot-after-us-fda-speeds-up-process-for-imfinzi-lung-cancer-drug-181697.html AstraZeneca's share price slump on Mystic trial unwarranted, says investor Neil Woodford https://www.proactiveinvestors.co.uk/companies/news/181654/astrazeneca-s-share-price-slump-on-mystic-trial-unwarranted-says-investor-neil-woodford-181654.html Fri, 28 Jul 2017 14:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/181654/astrazeneca-s-share-price-slump-on-mystic-trial-unwarranted-says-investor-neil-woodford-181654.html AstraZeneca – long road back for toxic drug giant https://www.proactiveinvestors.co.uk/companies/news/181565/astrazeneca-long-road-back-for-toxic-drug-giant-181565.html Thu, 27 Jul 2017 14:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/181565/astrazeneca-long-road-back-for-toxic-drug-giant-181565.html AstraZeneca - long road back for drugs giant https://www.proactiveinvestors.co.uk/companies/news/181596/astrazeneca-long-road-back-for-drugs-giant-181596.html Thu, 27 Jul 2017 13:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/181596/astrazeneca-long-road-back-for-drugs-giant-181596.html Billions wiped off AstraZeneca’s value as key lung cancer study fails to meet primary endpoint https://www.proactiveinvestors.co.uk/companies/news/181542/billions-wiped-off-astrazenecas-value-as-key-lung-cancer-study-fails-to-meet-primary-endpoint-181542.html Thu, 27 Jul 2017 07:47:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/181542/billions-wiped-off-astrazenecas-value-as-key-lung-cancer-study-fails-to-meet-primary-endpoint-181542.html AstraZeneca plummets on reports that CEO Pascal Soriot is set to join Israeli competitor Teva https://www.proactiveinvestors.co.uk/companies/news/180830/astrazeneca-plummets-on-reports-that-ceo-pascal-soriot-is-set-to-join-israeli-competitor-teva-180830.html Thu, 13 Jul 2017 08:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/180830/astrazeneca-plummets-on-reports-that-ceo-pascal-soriot-is-set-to-join-israeli-competitor-teva-180830.html GlaxoSmithKline and AstraZeneca among drug stocks buoyed by Trump’s healthcare plans https://www.proactiveinvestors.co.uk/companies/news/179725/glaxosmithkline-and-astrazeneca-among-drug-stocks-buoyed-by-trumps-healthcare-plans-179725.html Fri, 23 Jun 2017 06:41:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/179725/glaxosmithkline-and-astrazeneca-among-drug-stocks-buoyed-by-trumps-healthcare-plans-179725.html AstraZeneca raises initial US$200mln from sale of global rights to its Zomig treatment for migraines and cluster headaches https://www.proactiveinvestors.co.uk/companies/news/178895/astrazeneca-raises-initial-us200mln-from-sale-of-global-rights-to-its-zomig-treatment-for-migraines-and-cluster-headaches-178895.html Wed, 07 Jun 2017 08:33:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/178895/astrazeneca-raises-initial-us200mln-from-sale-of-global-rights-to-its-zomig-treatment-for-migraines-and-cluster-headaches-178895.html ASCO 2017: AstraZeneca’s breast cancer treatment leads the way https://www.proactiveinvestors.co.uk/companies/news/178779/asco-2017-astrazenecas-breast-cancer-treatment-leads-the-way-178779.html Mon, 05 Jun 2017 11:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/178779/asco-2017-astrazenecas-breast-cancer-treatment-leads-the-way-178779.html AstraZeneca’s Lynparza breast cancer drug impresses in phase III trial https://www.proactiveinvestors.co.uk/companies/news/178763/astrazenecas-lynparza-breast-cancer-drug-impresses-in-phase-iii-trial-178763.html Mon, 05 Jun 2017 07:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/178763/astrazenecas-lynparza-breast-cancer-drug-impresses-in-phase-iii-trial-178763.html AstraZeneca PLC 'one for the brave', but still a 'buy', according to leading City broker https://www.proactiveinvestors.co.uk/companies/news/177906/astrazeneca-plc-one-for-the-brave-but-still-a-buy-according-to-leading-city-broker-177906.html Wed, 17 May 2017 07:10:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/177906/astrazeneca-plc-one-for-the-brave-but-still-a-buy-according-to-leading-city-broker-177906.html Lung cancer success means AstraZeneca now has a “significant lead” over competitors https://www.proactiveinvestors.co.uk/companies/news/177794/lung-cancer-success-means-astrazeneca-now-has-a-significant-lead-over-competitors-177794.html Mon, 15 May 2017 09:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/177794/lung-cancer-success-means-astrazeneca-now-has-a-significant-lead-over-competitors-177794.html AstraZeneca, Merck and Bristol-Myers vying for dominance in lung cancer market https://www.proactiveinvestors.co.uk/companies/news/177723/astrazeneca-merck-and-bristol-myers-vying-for-dominance-in-lung-cancer-market-177723.html Sun, 14 May 2017 05:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/177723/astrazeneca-merck-and-bristol-myers-vying-for-dominance-in-lung-cancer-market-177723.html AstraZeneca reports “highly encouraging” initial results from its PACIFIC lung cancer trial https://www.proactiveinvestors.co.uk/companies/news/177702/astrazeneca-reports-highly-encouraging-initial-results-from-its-pacific-lung-cancer-trial-177702.html Fri, 12 May 2017 07:02:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/177702/astrazeneca-reports-highly-encouraging-initial-results-from-its-pacific-lung-cancer-trial-177702.html Is oil heading to US$41? - Tip TV https://www.proactiveinvestors.co.uk/companies/news/307403/is-oil-heading-to-us41-tip-tv-7403.html Fri, 05 May 2017 10:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/307403/is-oil-heading-to-us41-tip-tv-7403.html US Food & Drug administration gives accelerated approval to drug that uses body’s immune system to fight cancer https://www.proactiveinvestors.co.uk/companies/news/177165/us-food-drug-administration-gives-accelerated-approval-to-drug-that-uses-bodys-immune-system-to-fight-cancer-177165.html Tue, 02 May 2017 13:16:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/177165/us-food-drug-administration-gives-accelerated-approval-to-drug-that-uses-bodys-immune-system-to-fight-cancer-177165.html AstraZeneca’s new drugs can’t come quick enough https://www.proactiveinvestors.co.uk/companies/news/176992/astrazenecas-new-drugs-cant-come-quick-enough-176992.html Thu, 27 Apr 2017 08:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/176992/astrazenecas-new-drugs-cant-come-quick-enough-176992.html Drugs giant AstraZeneca's recommendation cut by Jefferies https://www.proactiveinvestors.co.uk/companies/news/176223/drugs-giant-astrazeneca-s-recommendation-cut-by-jefferies-176223.html Mon, 10 Apr 2017 11:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/176223/drugs-giant-astrazeneca-s-recommendation-cut-by-jefferies-176223.html Drug developer AstraZeneca shares mark time after FDA approval for lung cancer drug https://www.proactiveinvestors.co.uk/companies/news/175745/drug-developer-astrazeneca-shares-mark-time-after-fda-approval-for-lung-cancer-drug-175745.html Fri, 31 Mar 2017 07:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/175745/drug-developer-astrazeneca-shares-mark-time-after-fda-approval-for-lung-cancer-drug-175745.html AstraZeneca’s diabetes drug data shows significant cut in death rates https://www.proactiveinvestors.co.uk/companies/news/175060/astrazenecas-diabetes-drug-data-shows-significant-cut-in-death-rates-175060.html Mon, 20 Mar 2017 09:55:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/175060/astrazenecas-diabetes-drug-data-shows-significant-cut-in-death-rates-175060.html FDA deals another blow to AstraZeneca’s ZS-9 blood drug https://www.proactiveinvestors.co.uk/companies/news/174974/fda-deals-another-blow-to-astrazenecas-zs-9-blood-drug-174974.html Fri, 17 Mar 2017 08:18:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/174974/fda-deals-another-blow-to-astrazenecas-zs-9-blood-drug-174974.html Barclays Capital analysts "resoundingly positive" on pharma stocks; AstraZeneca top pick https://www.proactiveinvestors.co.uk/companies/news/174462/Barclays-Capital-analysts-%22resoundingly-positive%22-on-pharma-stocks-AstraZeneca-top-pick--174462.html Wed, 08 Mar 2017 11:08:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/174462/Barclays-Capital-analysts-%22resoundingly-positive%22-on-pharma-stocks-AstraZeneca-top-pick--174462.html US FDA approves AstraZeneca combination drug for treatment of type-2 diabetes https://www.proactiveinvestors.co.uk/companies/news/173904/us-fda-approves-astrazeneca-combination-drug-for-treatment-of-type-2-diabetes-173904.html Tue, 28 Feb 2017 09:32:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/173904/us-fda-approves-astrazeneca-combination-drug-for-treatment-of-type-2-diabetes-173904.html Look for dips in AstraZeneca share price - Zak Mir https://www.proactiveinvestors.co.uk/companies/news/306954/look-for-dips-in-astrazeneca-share-price-zak-mir-6954.html Tue, 21 Feb 2017 10:44:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/306954/look-for-dips-in-astrazeneca-share-price-zak-mir-6954.html AstraZeneca sells commercial rights to Zoladex cancer treatment https://www.proactiveinvestors.co.uk/companies/news/173395/astrazeneca-sells-commercial-rights-to-zoladex-cancer-treatment-173395.html Mon, 20 Feb 2017 11:50:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/173395/astrazeneca-sells-commercial-rights-to-zoladex-cancer-treatment-173395.html AstraZeneca reveals positive breast cancer treatment trial results; Woodford adds to holding https://www.proactiveinvestors.co.uk/companies/news/173310/astrazeneca-reveals-positive-breast-cancer-treatment-trial-results-woodford-adds-to-holding-173310.html Fri, 17 Feb 2017 08:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/173310/astrazeneca-reveals-positive-breast-cancer-treatment-trial-results-woodford-adds-to-holding-173310.html AstraZeneca: Never mind the sales, look at the dividend yield https://www.proactiveinvestors.co.uk/companies/news/172552/AstraZeneca-Never-mind-the-sales-look-at-the-dividend-yield--172552.html Thu, 02 Feb 2017 08:20:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/172552/AstraZeneca-Never-mind-the-sales-look-at-the-dividend-yield--172552.html Analysis charts an opportunity to buy AstraZeneca shares - Zak Mir https://www.proactiveinvestors.co.uk/companies/news/306805/analysis-charts-an-opportunity-to-buy-astrazeneca-shares-zak-mir-6805.html Fri, 27 Jan 2017 10:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/306805/analysis-charts-an-opportunity-to-buy-astrazeneca-shares-zak-mir-6805.html AstraZeneca rejigs MYSTIC lung cancer study https://www.proactiveinvestors.co.uk/companies/news/171730/astrazeneca-rejigs-mystic-lung-cancer-study-171730.html Tue, 17 Jan 2017 09:32:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/171730/astrazeneca-rejigs-mystic-lung-cancer-study-171730.html AstraZeneca cancer drug application accepted by FDA https://www.proactiveinvestors.co.uk/companies/news/170258/astrazeneca-cancer-drug-application-accepted-by-fda-170258.html Fri, 09 Dec 2016 21:45:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/170258/astrazeneca-cancer-drug-application-accepted-by-fda-170258.html Still some downside at AstraZeneca says Zak Mir https://www.proactiveinvestors.co.uk/companies/news/306576/still-some-downside-at-astrazeneca-says-zak-mir-6576.html Thu, 08 Dec 2016 12:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/306576/still-some-downside-at-astrazeneca-says-zak-mir-6576.html AstraZeneca top pick under UBS's new valuation method https://www.proactiveinvestors.co.uk/companies/news/170114/astrazeneca-top-pick-under-ubs-s-new-valuation-method-170114.html Wed, 07 Dec 2016 12:13:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/170114/astrazeneca-top-pick-under-ubs-s-new-valuation-method-170114.html Five reasons to buy AstraZeneca https://www.proactiveinvestors.co.uk/companies/news/169689/five-reasons-to-buy-astrazeneca-169689.html Tue, 29 Nov 2016 14:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/169689/five-reasons-to-buy-astrazeneca-169689.html AstraZeneca's MYSTIC trial has little appeal for JP Morgan https://www.proactiveinvestors.co.uk/companies/news/169609/astrazeneca-s-mystic-trial-has-little-appeal-for-jp-morgan-169609.html Mon, 28 Nov 2016 12:23:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/169609/astrazeneca-s-mystic-trial-has-little-appeal-for-jp-morgan-169609.html AztraZeneca a bargain, says this stock picker https://www.proactiveinvestors.co.uk/companies/news/169528/aztrazeneca-a-bargain-says-this-stock-picker-169528.html Fri, 25 Nov 2016 17:36:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/169528/aztrazeneca-a-bargain-says-this-stock-picker-169528.html AstraZeneca restarts cancer drug trials after US all clear https://www.proactiveinvestors.co.uk/companies/news/169322/astrazeneca-restarts-cancer-drug-trials-after-us-all-clear-169322.html Tue, 22 Nov 2016 08:16:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/169322/astrazeneca-restarts-cancer-drug-trials-after-us-all-clear-169322.html Is too great a risk of MYSTIC failure factored into AstraZeneca's price? https://www.proactiveinvestors.co.uk/companies/news/169136/is-too-great-a-risk-of-mystic-failure-factored-into-astrazeneca-s-price-169136.html Thu, 17 Nov 2016 10:18:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/169136/is-too-great-a-risk-of-mystic-failure-factored-into-astrazeneca-s-price-169136.html It's all about the pipelines for drugs giants Astra and Shire https://www.proactiveinvestors.co.uk/companies/news/168930/it-s-all-about-the-pipelines-for-drugs-giants-astra-and-shire-168930.html Mon, 14 Nov 2016 11:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/168930/it-s-all-about-the-pipelines-for-drugs-giants-astra-and-shire-168930.html AstraZeneca trial shows benefit of child asthma treatment https://www.proactiveinvestors.co.uk/companies/news/168871/astrazeneca-trial-shows-benefit-of-child-asthma-treatment-168871.html Fri, 11 Nov 2016 15:19:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/168871/astrazeneca-trial-shows-benefit-of-child-asthma-treatment-168871.html Immuno-therapy trials key for AstraZeneca says broker https://www.proactiveinvestors.co.uk/companies/news/168806/immuno-therapy-trials-key-for-astrazeneca-says-broker-168806.html Thu, 10 Nov 2016 10:01:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/168806/immuno-therapy-trials-key-for-astrazeneca-says-broker-168806.html AstraZeneca shares drop after cancer drug trial setback https://www.proactiveinvestors.co.uk/companies/news/168167/astrazeneca-shares-drop-after-cancer-drug-trial-setback-168167.html Thu, 27 Oct 2016 19:20:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/168167/astrazeneca-shares-drop-after-cancer-drug-trial-setback-168167.html AstraZeneca licenses out Crohn's antibody for US$250mln https://www.proactiveinvestors.co.uk/companies/news/166819/astrazeneca-licenses-out-crohn-s-antibody-for-us250mln-166819.html Mon, 03 Oct 2016 06:38:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/166819/astrazeneca-licenses-out-crohn-s-antibody-for-us250mln-166819.html AstraZeneca up after diabetes combo passes phase III https://www.proactiveinvestors.co.uk/companies/news/166025/astrazeneca-up-after-diabetes-combo-passes-phase-iii-166025.html Fri, 16 Sep 2016 14:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/166025/astrazeneca-up-after-diabetes-combo-passes-phase-iii-166025.html Ocado gets another pasting over margin warning https://www.proactiveinvestors.co.uk/companies/news/276019/ocado-gets-another-pasting-over-margin-warning-26019.html Wed, 14 Sep 2016 09:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/276019/ocado-gets-another-pasting-over-margin-warning-26019.html Broker talks up AstraZeneca's lung cancer drug prospects https://www.proactiveinvestors.co.uk/companies/news/275993/broker-talks-up-astrazeneca-s-lung-cancer-drug-prospects-25993.html Mon, 12 Sep 2016 08:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/275993/broker-talks-up-astrazeneca-s-lung-cancer-drug-prospects-25993.html AstraZeneca’s new asthma drug: “Late to the game, but potentially best in class” https://www.proactiveinvestors.co.uk/companies/news/159186/astrazenecas-new-asthma-drug-late-to-the-game-but-potentially-best-in-class-159186.html Tue, 06 Sep 2016 14:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/159186/astrazenecas-new-asthma-drug-late-to-the-game-but-potentially-best-in-class-159186.html AstraZeneca asthma treatment does well in final trial https://www.proactiveinvestors.co.uk/companies/news/149550/astrazeneca-asthma-treatment-does-well-in-final-trial-149550.html Mon, 05 Sep 2016 14:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/149550/astrazeneca-asthma-treatment-does-well-in-final-trial-149550.html AVIVA & ASTRAZENECA - Which will Sparkle? https://www.proactiveinvestors.co.uk/companies/news/275856/aviva-astrazeneca-which-will-sparkle-25856.html Sat, 27 Aug 2016 06:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/275856/aviva-astrazeneca-which-will-sparkle-25856.html AstraZeneca to sell antibiotics business to Pfizer https://www.proactiveinvestors.co.uk/companies/news/129657/astrazeneca-to-sell-antibiotics-business-to-pfizer-129657.html Wed, 24 Aug 2016 14:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/129657/astrazeneca-to-sell-antibiotics-business-to-pfizer-129657.html AstraZeneca's Alzheimer's drug fast-tracked by FDA https://www.proactiveinvestors.co.uk/companies/news/129567/astrazeneca-s-alzheimer-s-drug-fast-tracked-by-fda-129567.html Mon, 22 Aug 2016 13:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/129567/astrazeneca-s-alzheimer-s-drug-fast-tracked-by-fda-129567.html AstraZeneca combination fails final lung cancer trial, Array hit https://www.proactiveinvestors.co.uk/companies/news/129152/astrazeneca-combination-fails-final-lung-cancer-trial-array-hit-129152.html Tue, 09 Aug 2016 14:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/129152/astrazeneca-combination-fails-final-lung-cancer-trial-array-hit-129152.html Generics hound AstraZeneca despite Brilinta star turn https://www.proactiveinvestors.co.uk/companies/news/128739/generics-hound-astrazeneca-despite-brilinta-star-turn-128739.html Thu, 28 Jul 2016 08:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/128739/generics-hound-astrazeneca-despite-brilinta-star-turn-128739.html Successful lung cancer drug trial boosts AstraZeneca https://www.proactiveinvestors.co.uk/companies/news/128284/successful-lung-cancer-drug-trial-boosts-astrazeneca-128284.html Mon, 18 Jul 2016 07:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/128284/successful-lung-cancer-drug-trial-boosts-astrazeneca-128284.html AstraZeneca to take impairment after US recommends against flu vaccine https://www.proactiveinvestors.co.uk/companies/news/127437/astrazeneca-to-take-impairment-after-us-recommends-against-flu-vaccine-127437.html Thu, 23 Jun 2016 09:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/127437/astrazeneca-to-take-impairment-after-us-recommends-against-flu-vaccine-127437.html AstraZeneca does US$770mln anaesthetic deal https://www.proactiveinvestors.co.uk/companies/news/126922/astrazeneca-does-us770mln-anaesthetic-deal-126922.html Thu, 09 Jun 2016 06:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/126922/astrazeneca-does-us770mln-anaesthetic-deal-126922.html AstraZeneca bags US rights for gout-related drug https://www.proactiveinvestors.co.uk/companies/news/126711/astrazeneca-bags-us-rights-for-gout-related-drug-126711.html Fri, 03 Jun 2016 07:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/126711/astrazeneca-bags-us-rights-for-gout-related-drug-126711.html FDA's ZS-9 ruling just a "bump in the road" for AstraZeneca https://www.proactiveinvestors.co.uk/companies/news/275130/fda-s-zs-9-ruling-just-a-bump-in-the-road-for-astrazeneca-25130.html Tue, 31 May 2016 09:44:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/275130/fda-s-zs-9-ruling-just-a-bump-in-the-road-for-astrazeneca-25130.html AstraZeneca drug fails gastric cancer trial https://www.proactiveinvestors.co.uk/companies/news/126091/astrazeneca-drug-fails-gastric-cancer-trial-126091.html Wed, 18 May 2016 11:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/126091/astrazeneca-drug-fails-gastric-cancer-trial-126091.html AstraZeneca to cut costs but stays silent on M&A talk https://www.proactiveinvestors.co.uk/companies/news/125427/astrazeneca-to-cut-costs-but-stays-silent-on-ma-talk-125427.html Fri, 29 Apr 2016 12:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/125427/astrazeneca-to-cut-costs-but-stays-silent-on-ma-talk-125427.html AstraZeneca tipped to bid for US cancer specialist https://www.proactiveinvestors.co.uk/companies/news/124923/astrazeneca-tipped-to-bid-for-us-cancer-specialist-124923.html Mon, 18 Apr 2016 14:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/124923/astrazeneca-tipped-to-bid-for-us-cancer-specialist-124923.html AstraZeneca PLC's US$100mln boost as Eli Lilly collaboration moves to next stage https://www.proactiveinvestors.co.uk/companies/news/124581/astrazeneca-plc-s-us100mln-boost-as-eli-lilly-collaboration-moves-to-next-stage-124581.html Fri, 08 Apr 2016 07:56:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/124581/astrazeneca-plc-s-us100mln-boost-as-eli-lilly-collaboration-moves-to-next-stage-124581.html AstraZeneca's heart drug Brilinta fails in trial https://www.proactiveinvestors.co.uk/companies/news/124011/astrazeneca-s-heart-drug-brilinta-fails-in-trial-124011.html Wed, 23 Mar 2016 08:15:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/124011/astrazeneca-s-heart-drug-brilinta-fails-in-trial-124011.html AstraZeneca PLC lacks catalysts for 2016 - Jefferies https://www.proactiveinvestors.co.uk/companies/news/274500/astrazeneca-plc-lacks-catalysts-for-2016-jefferies-24500.html Tue, 15 Mar 2016 11:32:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/274500/astrazeneca-plc-lacks-catalysts-for-2016-jefferies-24500.html Jefferies downgrades targets on Glaxo and Astra https://www.proactiveinvestors.co.uk/companies/news/274310/jefferies-downgrades-targets-on-glaxo-and-astra-24310.html Mon, 22 Feb 2016 12:21:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/274310/jefferies-downgrades-targets-on-glaxo-and-astra-24310.html AstraZeneca gets US boost for bladder cancer drug https://www.proactiveinvestors.co.uk/companies/news/122628/astrazeneca-gets-us-boost-for-bladder-cancer-drug-122628.html Wed, 17 Feb 2016 10:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/122628/astrazeneca-gets-us-boost-for-bladder-cancer-drug-122628.html AstraZeneca's earnings rise in 2015 but sees fall this year https://www.proactiveinvestors.co.uk/companies/news/122149/astrazeneca-s-earnings-rise-in-2015-but-sees-fall-this-year-122149.html Thu, 04 Feb 2016 08:45:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/122149/astrazeneca-s-earnings-rise-in-2015-but-sees-fall-this-year-122149.html What next for deal-making in 2016? https://www.proactiveinvestors.co.uk/companies/news/120865/what-next-for-deal-making-in-2016-120865.html Mon, 28 Dec 2015 11:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/120865/what-next-for-deal-making-in-2016-120865.html Thursday's trending - pharma, Fed rates and Astrazeneca https://www.proactiveinvestors.co.uk/companies/news/120619/thursday-s-trending-pharma-fed-rates-and-astrazeneca-120619.html Thu, 17 Dec 2015 17:56:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/120619/thursday-s-trending-pharma-fed-rates-and-astrazeneca-120619.html AstraZeneca buys cancer drug developer for US$4bn https://www.proactiveinvestors.co.uk/companies/news/120571/astrazeneca-buys-cancer-drug-developer-for-us4bn-120571.html Thu, 17 Dec 2015 07:50:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/120571/astrazeneca-buys-cancer-drug-developer-for-us4bn-120571.html AstraZeneca's pre-Christmas spending spree continues https://www.proactiveinvestors.co.uk/companies/news/120524/astrazeneca-s-pre-christmas-spending-spree-continues-120524.html Wed, 16 Dec 2015 08:27:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/120524/astrazeneca-s-pre-christmas-spending-spree-continues-120524.html AstraZeneca in deal talks with Acerta Pharma https://www.proactiveinvestors.co.uk/companies/news/120413/astrazeneca-in-deal-talks-with-acerta-pharma-120413.html Mon, 14 Dec 2015 10:33:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/120413/astrazeneca-in-deal-talks-with-acerta-pharma-120413.html AstraZeneca gets big upgrade from Morgan Stanley https://www.proactiveinvestors.co.uk/companies/news/119971/astrazeneca-gets-big-upgrade-from-morgan-stanley-119971.html Wed, 02 Dec 2015 15:19:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/119971/astrazeneca-gets-big-upgrade-from-morgan-stanley-119971.html Investors urged to take closer look at Astra’s lupus drug trial https://www.proactiveinvestors.co.uk/companies/news/273595/investors-urged-to-take-closer-look-at-astras-lupus-drug-trial-23595.html Thu, 12 Nov 2015 09:21:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/273595/investors-urged-to-take-closer-look-at-astras-lupus-drug-trial-23595.html AstraZeneca lupus drug cuts disease activity in mid-stage trial https://www.proactiveinvestors.co.uk/companies/news/117319/astrazeneca-lupus-drug-cuts-disease-activity-in-mid-stage-trial-117319.html Tue, 10 Nov 2015 15:09:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/117319/astrazeneca-lupus-drug-cuts-disease-activity-in-mid-stage-trial-117319.html More M&A to follow AstraZeneca tie-up with ZS Pharma https://www.proactiveinvestors.co.uk/companies/news/117188/more-ma-to-follow-astrazeneca-tie-up-with-zs-pharma-117188.html Fri, 06 Nov 2015 13:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/117188/more-ma-to-follow-astrazeneca-tie-up-with-zs-pharma-117188.html AstraZeneca to buy US drug firm ZS Pharma for $2.7bn https://www.proactiveinvestors.co.uk/companies/news/117164/astrazeneca-to-buy-us-drug-firm-zs-pharma-for-27bn-117164.html Fri, 06 Nov 2015 07:45:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/117164/astrazeneca-to-buy-us-drug-firm-zs-pharma-for-27bn-117164.html AstraZeneca upgrade cheers despite Crestor warning https://www.proactiveinvestors.co.uk/companies/news/117130/astrazeneca-upgrade-cheers-despite-crestor-warning-117130.html Thu, 05 Nov 2015 12:55:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/117130/astrazeneca-upgrade-cheers-despite-crestor-warning-117130.html AstraZeneca ups profit guidance but sees tough 2016 https://www.proactiveinvestors.co.uk/companies/news/117113/astrazeneca-ups-profit-guidance-but-sees-tough-2016-117113.html Thu, 05 Nov 2015 08:55:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/117113/astrazeneca-ups-profit-guidance-but-sees-tough-2016-117113.html AstraZeneca's main headaches: FX, generics and slowing Chinese growth https://www.proactiveinvestors.co.uk/companies/news/117082/astrazeneca-s-main-headaches-fx-generics-and-slowing-chinese-growth-117082.html Wed, 04 Nov 2015 15:43:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/117082/astrazeneca-s-main-headaches-fx-generics-and-slowing-chinese-growth-117082.html AstraZeneca gout drug approval seen as mild positive https://www.proactiveinvestors.co.uk/companies/news/116643/astrazeneca-gout-drug-approval-seen-as-mild-positive-116643.html Mon, 26 Oct 2015 09:23:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/116643/astrazeneca-gout-drug-approval-seen-as-mild-positive-116643.html AstraZeneca gets shot in the arm from Deutsche https://www.proactiveinvestors.co.uk/companies/news/273106/astrazeneca-gets-shot-in-the-arm-from-deutsche-23106.html Mon, 14 Sep 2015 11:06:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/273106/astrazeneca-gets-shot-in-the-arm-from-deutsche-23106.html AstraZeneca gets new FDA approval for heart drug https://www.proactiveinvestors.co.uk/companies/news/110536/astrazeneca-gets-new-fda-approval-for-heart-drug-110536.html Fri, 04 Sep 2015 11:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/110536/astrazeneca-gets-new-fda-approval-for-heart-drug-110536.html Woodford fund proving a summer favourite for investors https://www.proactiveinvestors.co.uk/companies/news/110464/woodford-fund-proving-a-summer-favourite-for-investors-110464.html Wed, 02 Sep 2015 10:13:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/110464/woodford-fund-proving-a-summer-favourite-for-investors-110464.html AstraZeneca licenses psoriasis rights to Valeant https://www.proactiveinvestors.co.uk/companies/news/110429/astrazeneca-licenses-psoriasis-rights-to-valeant-110429.html Tue, 01 Sep 2015 13:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/110429/astrazeneca-licenses-psoriasis-rights-to-valeant-110429.html AstraZeneca nabs rival's executive https://www.proactiveinvestors.co.uk/companies/news/110216/astrazeneca-nabs-rival-s-executive-110216.html Mon, 24 Aug 2015 10:08:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/110216/astrazeneca-nabs-rival-s-executive-110216.html AstraZeneca to pay Inovio Pharma $727 mln to produce cancer vaccine https://www.proactiveinvestors.co.uk/companies/news/109837/astrazeneca-to-pay-inovio-pharma-727-mln-to-produce-cancer-vaccine-109837.html Mon, 10 Aug 2015 16:28:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/109837/astrazeneca-to-pay-inovio-pharma-727-mln-to-produce-cancer-vaccine-109837.html UPDATE - AstraZeneca expects new products to see off generics https://www.proactiveinvestors.co.uk/companies/news/109508/update-astrazeneca-expects-new-products-to-see-off-generics-109508.html Thu, 30 Jul 2015 14:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/109508/update-astrazeneca-expects-new-products-to-see-off-generics-109508.html AstraZeneca wins US approval for cancer drug https://www.proactiveinvestors.co.uk/companies/news/108975/astrazeneca-wins-us-approval-for-cancer-drug-108975.html Tue, 14 Jul 2015 09:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/108975/astrazeneca-wins-us-approval-for-cancer-drug-108975.html Cancer drug firms to cash in on $9bn immunotherapy market https://www.proactiveinvestors.co.uk/companies/news/107954/cancer-drug-firms-to-cash-in-on-9bn-immunotherapy-market-107954.html Thu, 11 Jun 2015 14:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/107954/cancer-drug-firms-to-cash-in-on-9bn-immunotherapy-market-107954.html AstraZeneca "to miss out on US drug deal" - sources https://www.proactiveinvestors.co.uk/companies/news/107864/astrazeneca-to-miss-out-on-us-drug-deal-sources-107864.html Tue, 09 Jun 2015 13:57:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/107864/astrazeneca-to-miss-out-on-us-drug-deal-sources-107864.html UPDATE - Currency moves hit AstraZeneca's sales https://www.proactiveinvestors.co.uk/companies/news/68368/update-currency-moves-hit-astrazenecas-sales-79642.html Fri, 24 Apr 2015 09:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/68368/update-currency-moves-hit-astrazenecas-sales-79642.html AstraZeneca lung cancer drug fast-tracked to market https://www.proactiveinvestors.co.uk/companies/news/68044/astrazeneca-lung-cancer-drug-fast-tracked-to-market-79294.html Wed, 15 Apr 2015 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/68044/astrazeneca-lung-cancer-drug-fast-tracked-to-market-79294.html AstraZeneca: The medication is working https://www.proactiveinvestors.co.uk/companies/news/266134/astrazeneca-the-medication-is-working-17766.html AstraZeneca has an exciting pipeline, a strong dividend yield, good cashflow and M&A potential, which combined with the close proximity of major technical support, offers an opportunity to buy shares.

]]>
Sat, 07 Feb 2015 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/266134/astrazeneca-the-medication-is-working-17766.html
AstraZeneca disappoints with fourth quarter earnings https://www.proactiveinvestors.co.uk/companies/news/65938/astrazeneca-disappoints-with-fourth-quarter-earnings-76980.html Anglo-Swedish pharmaceuticals giant AstraZeneca unveiled a fall in profits despite notching up the fourth consecutive quarter of revenue growth.

]]>
Thu, 05 Feb 2015 08:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/65938/astrazeneca-disappoints-with-fourth-quarter-earnings-76980.html
AstraZeneca shares flat despite bullish sales update https://www.proactiveinvestors.co.uk/companies/news/63383/astrazeneca-shares-flat-despite-bullish-sales-update--74058.html Thu, 06 Nov 2014 07:21:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/63383/astrazeneca-shares-flat-despite-bullish-sales-update--74058.html Tax inversion worries turn drug stocks on their head, wiping £8bn off value of sector https://www.proactiveinvestors.co.uk/companies/news/62724/tax-inversion-worries-turn-drug-stocks-on-their-head-wiping-8bn-off-value-of-sector-73279.html Almost £8bn was wiped off the value of the healthcare sector after AbbVie said it was reconsidering its £32bn bid for Shire.

]]>
Wed, 15 Oct 2014 10:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/62724/tax-inversion-worries-turn-drug-stocks-on-their-head-wiping-8bn-off-value-of-sector-73279.html
AstraZeneca bolsters defences with strong sales https://www.proactiveinvestors.co.uk/companies/news/60464/astrazeneca-bolsters-defences-with-strong-sales-70869.html Thu, 31 Jul 2014 08:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/60464/astrazeneca-bolsters-defences-with-strong-sales-70869.html What next for AstraZeneca? https://www.proactiveinvestors.co.uk/companies/news/264746/what-next-for-astrazeneca--16317.html The proposed £55 a share takeover would have been the largest ever of a UK firm by a foreign company, but what now for AstraZeneca?

]]>
Sat, 31 May 2014 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/264746/what-next-for-astrazeneca--16317.html
UPDATE - Pfizer abandons AstraZeneca takeover plans https://www.proactiveinvestors.co.uk/companies/news/58558/update-pfizer-abandons-astrazeneca-takeover-plans-68854.html The US drugs giant's failed courtship of Astra may lead to changes in laws on both sides of the Atlantic.

]]>
Tue, 27 May 2014 09:07:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/58558/update-pfizer-abandons-astrazeneca-takeover-plans-68854.html
More Astra shareholders query decision to reject Pfizer https://www.proactiveinvestors.co.uk/companies/news/58404/more-astra-shareholders-query-decision-to-reject-pfizer-68684.html Tue, 20 May 2014 12:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/58404/more-astra-shareholders-query-decision-to-reject-pfizer-68684.html AstraZeneca rejects final proposal from Pfizer https://www.proactiveinvestors.co.uk/companies/news/58350/astrazeneca-rejects-final-proposal-from-pfizer-68630.html If the tumbling share price of AstraZeneca is any indication, the proposed bid from US rival is dead in the water.

]]>
Mon, 19 May 2014 08:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/58350/astrazeneca-rejects-final-proposal-from-pfizer-68630.html
AstraZeneca teams up with Incyte in cancer study https://www.proactiveinvestors.co.uk/companies/news/58232/astrazeneca-teams-up-with-incyte-in-cancer-study-68506.html Wed, 14 May 2014 09:10:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/58232/astrazeneca-teams-up-with-incyte-in-cancer-study-68506.html FTSE 100 approaches apogee, driven by pharmas and miners https://www.proactiveinvestors.co.uk/companies/news/58190/ftse-100-approaches-apogee-driven-by-pharmas-and-miners-68466.html Footsie is within 100 points of its all-time high, set on 30 December, 1999.

]]>
Tue, 13 May 2014 15:41:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/58190/ftse-100-approaches-apogee-driven-by-pharmas-and-miners-68466.html
AstraZeneca PLC heart pill gets US approval while Pfizer bid battle turns political https://www.proactiveinvestors.co.uk/companies/news/57982/astrazeneca-plc-heart-pill-gets-us-approval-while-pfizer-bid-battle-turns-political-68245.html Tue, 06 May 2014 10:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/57982/astrazeneca-plc-heart-pill-gets-us-approval-while-pfizer-bid-battle-turns-political-68245.html BarCap considers potential raid on European companies by US giants https://www.proactiveinvestors.co.uk/companies/news/57921/barcap-considers-potential-raid-on-european-companies-by-us-giants--68180.html Watch out Europe, the Americans are coming. This seems to be the essence of a report compiled by Barclays Capital, which assesses a potential raid on European companies by cashed up US corporate super-powers.

]]>
Mon, 05 May 2014 08:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/57921/barcap-considers-potential-raid-on-european-companies-by-us-giants--68180.html
UPDATE - AstraZeneca rejects higher Pfizer bid https://www.proactiveinvestors.co.uk/companies/news/57902/update-astrazeneca-rejects-higher-pfizer-bid-68161.html Fri, 02 May 2014 12:28:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/57902/update-astrazeneca-rejects-higher-pfizer-bid-68161.html UPDATE - AstraZeneca rebuffs Pfizer https://www.proactiveinvestors.co.uk/companies/news/57724/update-astrazeneca-rebuffs-pfizer--67976.html If the US drugs giant has its way, we'll soon be spared the ordeal of referring to AstraZeneca as an Anglo-Swedish company. Astra's under fire management has other ideas.

]]>
Mon, 28 Apr 2014 11:53:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/57724/update-astrazeneca-rebuffs-pfizer--67976.html
AstraZeneca vulnerable after recent rumours https://www.proactiveinvestors.co.uk/companies/news/264464/astrazeneca-vulnerable-after-recent-rumours--16029.html Sat, 26 Apr 2014 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/264464/astrazeneca-vulnerable-after-recent-rumours--16029.html AstraZeneca quiet on Pfizer bid https://www.proactiveinvestors.co.uk/companies/news/57635/astrazeneca-quiet-on-pfizer-bid-67879.html Thu, 24 Apr 2014 07:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/57635/astrazeneca-quiet-on-pfizer-bid-67879.html AstraZeneca shares fall as headwinds persist https://www.proactiveinvestors.co.uk/companies/news/55462/astrazeneca-shares-fall-as-headwinds-persist-65575.html Thu, 06 Feb 2014 07:44:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/55462/astrazeneca-shares-fall-as-headwinds-persist-65575.html AstraZeneca rated 'buy' as UBS initiates coverage of the European pharma sector https://www.proactiveinvestors.co.uk/companies/news/54692/astrazeneca-rated-buy-as-ubs-initiates-coverage-of-the-european-pharma-sector-64735.html The heavyweight broker UBS has initiated its coverage of the pharma sector with AstraZeneca as one of its ‘buy’ calls. It reckons the industry has survived the patent cliff and has emerged at fair value.

]]>
Fri, 10 Jan 2014 09:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/54692/astrazeneca-rated-buy-as-ubs-initiates-coverage-of-the-european-pharma-sector-64735.html
AstraZeneca downgraded by Panmure after new statins guidelines https://www.proactiveinvestors.co.uk/companies/news/53231/astrazeneca-downgraded-by-panmure-after-new-statins-guidelines--63188.html Wed, 13 Nov 2013 10:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/53231/astrazeneca-downgraded-by-panmure-after-new-statins-guidelines--63188.html AstraZeneca names new CFO as earnings fall https://www.proactiveinvestors.co.uk/companies/news/52854/astrazeneca-names-new-cfo-as-earnings-fall-62765.html Thu, 31 Oct 2013 10:32:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/52854/astrazeneca-names-new-cfo-as-earnings-fall-62765.html AstraZeneca's US$500mln deal a head turner for biotech sector https://www.proactiveinvestors.co.uk/companies/news/50768/astrazenecas-us500mln-deal-a-head-turner-for-biotech-sector-60404.html Expect a further ripple of excitement across the already pumped up US biotechnology sector after a head-turner of a deal by MedImmune, the US off-shoot of AstraZeneca.

]]>
Tue, 27 Aug 2013 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/50768/astrazenecas-us500mln-deal-a-head-turner-for-biotech-sector-60404.html
AstraZeneca boss: We ‘double and triple checked’ Chinese controls https://www.proactiveinvestors.co.uk/companies/news/50099/astrazeneca-boss-we-double-and-triple-checked-chinese-controls-59653.html Thu, 01 Aug 2013 15:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/50099/astrazeneca-boss-we-double-and-triple-checked-chinese-controls-59653.html AstraZeneca boss sees progress despite profits slide https://www.proactiveinvestors.co.uk/companies/news/50084/astrazeneca-boss-sees-progress-despite-profits-slide-59635.html Thu, 01 Aug 2013 08:14:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/50084/astrazeneca-boss-sees-progress-despite-profits-slide-59635.html Chinese investigate Astra as Glaxo admits breaches https://www.proactiveinvestors.co.uk/companies/news/49749/chinese-investigate-astra-as-glaxo-admits-breaches-59246.html Mon, 22 Jul 2013 09:42:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/49749/chinese-investigate-astra-as-glaxo-admits-breaches-59246.html AstraZeneca bags a billion dollar Pearl https://www.proactiveinvestors.co.uk/companies/news/48516/astrazeneca-bags-a-billion-dollar-pearl-57817.html AstraZeneca is buying in its next potential blockbuster drug in a deal that could eventually cost it over US$1bn.

]]>
Mon, 10 Jun 2013 07:26:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/48516/astrazeneca-bags-a-billion-dollar-pearl-57817.html
AstraZeneca: City brokers downbeat as drug sales tumble https://www.proactiveinvestors.co.uk/companies/news/47142/astrazeneca-city-brokers-downbeat-as-drug-sales-tumble-56212.html Around £1bn has been wiped from the value of AstraZeneca after quarterly sales fell by a worse-than-expected 12% and operating profits tumbled by a fifth.

]]>
Thu, 25 Apr 2013 11:03:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/47142/astrazeneca-city-brokers-downbeat-as-drug-sales-tumble-56212.html
AstraZeneca shares rise after latest strategic review is unveiled https://www.proactiveinvestors.co.uk/companies/news/46122/astrazeneca-shares-rise-after-latest-strategic-review-is-unveiled-55029.html Shares in the smaller of Britain’s two major drugs groups rose today as it unveiled another round of cost cuts designed to revive its fortunes.

]]>
Thu, 21 Mar 2013 11:11:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/46122/astrazeneca-shares-rise-after-latest-strategic-review-is-unveiled-55029.html
AstraZeneca, GlaxoSmithKline feel the chill from JP MorganCazenove https://www.proactiveinvestors.co.uk/companies/news/44866/astrazeneca-glaxosmithkline-feel-the-chill-from-jp-morgancazenove-53527.html  

JP Morgan this morning gave a rather downbeat assessment on the prospects of Britain’s ‘big two’ drugs companies.

 

]]>
Mon, 11 Feb 2013 10:29:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/44866/astrazeneca-glaxosmithkline-feel-the-chill-from-jp-morgancazenove-53527.html
Patent cliff weighs on AstraZeneca” or “AstraZeneca: Sedated as patents expire https://www.proactiveinvestors.co.uk/companies/news/260547/patent-cliff-weighs-on-astrazeneca-or-astrazeneca-sedated-as-patents-expire-12046.html

Drug maker AstraZeneca warned this week that sharp declines in revenue and earnings would continue through 2013, as the company struggles to right itself after losing patents on many key drugs

]]>
Sat, 09 Feb 2013 07:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/260547/patent-cliff-weighs-on-astrazeneca-or-astrazeneca-sedated-as-patents-expire-12046.html
No sugar coating as AstraZeneca warns of tough year ahead https://www.proactiveinvestors.co.uk/companies/news/44527/no-sugar-coating-as-astrazeneca-warns-of-tough-year-ahead-53115.html Thu, 31 Jan 2013 08:48:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/44527/no-sugar-coating-as-astrazeneca-warns-of-tough-year-ahead-53115.html AstraZeneca: SocGen says 'sell' after predicting less than brilliant outlook for Brilinta https://www.proactiveinvestors.co.uk/companies/news/44153/astrazeneca-socgen-says-sell-after-predicting-less-than-brilliant-outlook-for-brilinta-52681.html SocGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant AstraZeneca. Its negativity is based around what it expects to be the less-than-brilliant performance of heart and stroke drug Brilinta. It predicts other new products such as Onglyza and Bydureon (both for diabetes) will sell at a faster pace than most analysts are currently projecting.

 

]]>
Mon, 21 Jan 2013 11:13:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/44153/astrazeneca-socgen-says-sell-after-predicting-less-than-brilliant-outlook-for-brilinta-52681.html
AstraZeneca appoints Roche’s pharma head as new CEO https://www.proactiveinvestors.co.uk/companies/news/39678/astrazeneca-appoints-roches-pharma-head-as-new-ceo-47371.html Tue, 28 Aug 2012 09:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/39678/astrazeneca-appoints-roches-pharma-head-as-new-ceo-47371.html AstraZeneca reaffirms full year guidance despite sharp drop in profits https://www.proactiveinvestors.co.uk/companies/news/38503/astrazeneca-reaffirms-full-year-guidance-despite-sharp-drop-in-profits-46041.html Thu, 26 Jul 2012 08:49:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/38503/astrazeneca-reaffirms-full-year-guidance-despite-sharp-drop-in-profits-46041.html AstraZeneca: Vulnerable to a correction https://www.proactiveinvestors.co.uk/companies/news/258575/astrazeneca-vulnerable-to-a-correction-9879.html AstraZeneca still trades on a lowly 7.8x earnings, a significant discount to sector peers, but with little progress on the languishing drug pipeline, time is running out for a turnaround

]]>
Sat, 07 Jul 2012 07:00:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/258575/astrazeneca-vulnerable-to-a-correction-9879.html
Best remedy for AstraZeneca is AbbVie merger, says broker https://www.proactiveinvestors.co.uk/companies/news/37077/best-remedy-for-astrazeneca-is-abbvie-merger-says-broker-44336.html Tue, 19 Jun 2012 09:59:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/37077/best-remedy-for-astrazeneca-is-abbvie-merger-says-broker-44336.html Pharma sector progressing steadily through trough year, says broker https://www.proactiveinvestors.co.uk/companies/news/35594/pharma-sector-progressing-steadily-through-trough-year-says-broker-42523.html Wed, 09 May 2012 07:23:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/35594/pharma-sector-progressing-steadily-through-trough-year-says-broker-42523.html AstraZeneca added to UBS’s Key Calls list despite poor results https://www.proactiveinvestors.co.uk/companies/news/35484/astrazeneca-added-to-ubss-key-calls-list-despite-poor-results-42379.html Fri, 04 May 2012 10:44:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/35484/astrazeneca-added-to-ubss-key-calls-list-despite-poor-results-42379.html AstraZeneca: JP Morgan Cazenove sees limited further downside; upgrades to 'neutral' https://www.proactiveinvestors.co.uk/companies/news/35294/astrazeneca-jp-morgan-cazenove-sees-limited-further-downside-upgrades-to-neutral-42123.html Mon, 30 Apr 2012 10:43:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/35294/astrazeneca-jp-morgan-cazenove-sees-limited-further-downside-upgrades-to-neutral-42123.html AstraZeneca CEO quits as profits slump - UPDATE https://www.proactiveinvestors.co.uk/companies/news/35189/astrazeneca-ceo-quits-as-profits-slump-update-42000.html Thu, 26 Apr 2012 12:59:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/35189/astrazeneca-ceo-quits-as-profits-slump-update-42000.html AstraZeneca CEO quits as profits slump https://www.proactiveinvestors.co.uk/companies/news/35177/astrazeneca-ceo-quits-as-profits-slump-41985.html Thu, 26 Apr 2012 08:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/35177/astrazeneca-ceo-quits-as-profits-slump-41985.html AstraZeneca to acquire gout-focused US biotech for $1.3bln https://www.proactiveinvestors.co.uk/companies/news/35007/astrazeneca-to-acquire-gout-focused-us-biotech-for-13bln-41771.html Mon, 23 Apr 2012 06:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/35007/astrazeneca-to-acquire-gout-focused-us-biotech-for-13bln-41771.html AstraZeneca blow over Seroquel competition https://www.proactiveinvestors.co.uk/companies/news/34155/astrazeneca-blow-over-seroquel-competition-40714.html Mon, 26 Mar 2012 07:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/34155/astrazeneca-blow-over-seroquel-competition-40714.html AstraZeneca: A Healthy Option https://www.proactiveinvestors.co.uk/companies/news/257034/astrazeneca-a-healthy-option-8385.html AstraZeneca shows the rangebound trading experienced over the past year, with recent weakness dragging the share price towards major historical support at 2792p and 2700p. The oscillators are sliding into oversold territory, but still have a little way to go before indicating a buy signal.

]]>
Sat, 18 Feb 2012 10:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/257034/astrazeneca-a-healthy-option-8385.html
AstraZeneca hit by drug trial disappointments; takes Q4 charge of US$381 mln https://www.proactiveinvestors.co.uk/companies/news/31081/astrazeneca-hit-by-drug-trial-disappointments-takes-q4-charge-of-us381-mln-37164.html Tue, 20 Dec 2011 09:06:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/31081/astrazeneca-hit-by-drug-trial-disappointments-takes-q4-charge-of-us381-mln-37164.html AstraZeneca tumbles 3 per cent after trial failure and Morgan Stanley downgrade https://www.proactiveinvestors.co.uk/companies/news/29541/astrazeneca-tumbles-3-per-cent-after-trial-failure-and-morgan-stanley-downgrade-35317.html Tue, 08 Nov 2011 10:09:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/29541/astrazeneca-tumbles-3-per-cent-after-trial-failure-and-morgan-stanley-downgrade-35317.html AstraZeneca reveals inconclusive results for its landmark SATURN study on Crestor https://www.proactiveinvestors.co.uk/companies/news/27345/AstraZeneca-reveals-inconclusive-results-for-its-landmark-SATURN-study-on-Crestor-32662.html Fri, 02 Sep 2011 07:12:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/27345/AstraZeneca-reveals-inconclusive-results-for-its-landmark-SATURN-study-on-Crestor-32662.html Take your medicine with lowly rated AstraZeneca https://www.proactiveinvestors.co.uk/companies/news/254706/take-your-medicine-with-lowly-rated-astrazeneca-6053.html An ageing population and robust demand for AstraZeneca’s products in times of tough economic conditions create a strong balance sheet with defensive attractions.

 

]]>
Sat, 30 Jul 2011 09:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/254706/take-your-medicine-with-lowly-rated-astrazeneca-6053.html
AstraZeneca raises 2011 earnings guidance https://www.proactiveinvestors.co.uk/companies/news/26178/astrazeneca-raises-2011-earnings-guidance-31247.html Thu, 28 Jul 2011 09:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/26178/astrazeneca-raises-2011-earnings-guidance-31247.html AstraZeneca gets FDA approval for its Brilinta cardiovascular drug https://www.proactiveinvestors.co.uk/companies/news/25935/astrazeneca-gets-fda-approval-for-its-brilinta-cardiovascular-drug-30962.html AstraZeneca got some welcome news today when the US Food and Drug Adminstration approved its blood-thinning drug Brilinta. Analysts still have mixed views of the FTSE-100 pharmaceutical company’s shares, though

]]>
Thu, 21 Jul 2011 10:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/25935/astrazeneca-gets-fda-approval-for-its-brilinta-cardiovascular-drug-30962.html
FDA rejects AstraZeneca drug as new treatment for diabetes https://www.proactiveinvestors.co.uk/companies/news/25884/fda-rejects-astrazeneca-drug-as-new-treatment-for-diabetes-30900.html Question marks at the FDA about AstraZeneca’s Dapaglifozin drug have led to weakness in the company’s shares today. Analyst at three major investment banks have varying opinions of where they are headed

]]>
Wed, 20 Jul 2011 10:22:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/25884/fda-rejects-astrazeneca-drug-as-new-treatment-for-diabetes-30900.html
AstraZeneca agrees to US$198m Seroquel settlement https://www.proactiveinvestors.co.uk/companies/news/16454/astrazeneca-agrees-to-us198m-seroquel-settlement-19817.html Mon, 09 Aug 2010 07:45:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/16454/astrazeneca-agrees-to-us198m-seroquel-settlement-19817.html AstraZeneca surges after US District Court upholds Crestor patents until 2016 https://www.proactiveinvestors.co.uk/companies/news/15086/astrazeneca-surges-after-us-district-court-upholds-crestor-patents-until-2016-18281.html Wed, 30 Jun 2010 08:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/15086/astrazeneca-surges-after-us-district-court-upholds-crestor-patents-until-2016-18281.html AstraZeneca and Teva Pharmaceuticals settle patent dispute over generic version of Entocort EC https://www.proactiveinvestors.co.uk/companies/news/13651/astrazeneca-and-teva-pharmaceuticals-settle-patent-dispute-over-generic-version-of-entocort-ec-16655.html Tue, 18 May 2010 07:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/13651/astrazeneca-and-teva-pharmaceuticals-settle-patent-dispute-over-generic-version-of-entocort-ec-16655.html AstraZeneca and India's Torrent Pharma agree ‘branded generics’ supply deal https://www.proactiveinvestors.co.uk/companies/news/11593/astrazeneca-and-indias-torrent-pharma-agree-branded-generics-supply-deal-14286.html Thu, 11 Mar 2010 07:48:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/11593/astrazeneca-and-indias-torrent-pharma-agree-branded-generics-supply-deal-14286.html AstraZeneca pays £505m to settle dispute with HM Revenue & Customs https://www.proactiveinvestors.co.uk/companies/news/11022/astrazeneca-pays-505m-to-settle-dispute-with-hm-revenue-customs--13645.html Tue, 23 Feb 2010 12:45:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/11022/astrazeneca-pays-505m-to-settle-dispute-with-hm-revenue-customs--13645.html AstraZeneca and Rigel Pharmaceuticals seal license deal for rheumatoid arthritis drug https://www.proactiveinvestors.co.uk/companies/news/10785/astrazeneca-and-rigel-pharmaceuticals-seal-license-deal-for-rheumatoid-arthritis-drug-13372.html Tue, 16 Feb 2010 09:27:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/10785/astrazeneca-and-rigel-pharmaceuticals-seal-license-deal-for-rheumatoid-arthritis-drug-13372.html AstraZeneca’s CRESTOR gets FDA approval for use in stroke and heart disease prevention https://www.proactiveinvestors.co.uk/companies/news/10532/astrazenecas-crestor-gets-fda-approval-for-use-in-stroke-and-heart-disease-prevention-13092.html Tue, 09 Feb 2010 06:46:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/10532/astrazenecas-crestor-gets-fda-approval-for-use-in-stroke-and-heart-disease-prevention-13092.html AstraZeneca settles Nexium and Prilosec patent litigation with Teva Pharmaceutical https://www.proactiveinvestors.co.uk/companies/news/9501/astrazeneca-settles-nexium-and-prilosec-patent-litigation-with-teva-pharmaceutical-11903.html Thu, 07 Jan 2010 07:16:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/9501/astrazeneca-settles-nexium-and-prilosec-patent-litigation-with-teva-pharmaceutical-11903.html AstraZeneca’s CRESTOR Treatment for Cardiovascular Disease Receives Support from FDA’s Advisory Committee https://www.proactiveinvestors.co.uk/companies/news/9068/astrazenecas-crestor-treatment-for-cardiovascular-disease-receives-support-from-fdas-advisory-committee-11406.html Wed, 16 Dec 2009 07:32:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/9068/astrazenecas-crestor-treatment-for-cardiovascular-disease-receives-support-from-fdas-advisory-committee-11406.html AstraZeneca Receives FDA Approval For SEROQUEL Drug For Major Depressive Disorder https://www.proactiveinvestors.co.uk/companies/news/8710/astrazeneca-receives-fda-approval-for-seroquel-drug-for-major-depressive-disorder--10957.html Fri, 04 Dec 2009 07:33:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/8710/astrazeneca-receives-fda-approval-for-seroquel-drug-for-major-depressive-disorder--10957.html AstraZeneca And Targacept Ink License Deal For Major Depressive Disorder Drug https://www.proactiveinvestors.co.uk/companies/news/8659/astrazeneca-and-targacept-ink-license-deal-for-major-depressive-disorder-drug-10897.html Thu, 03 Dec 2009 07:48:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/8659/astrazeneca-and-targacept-ink-license-deal-for-major-depressive-disorder-drug-10897.html AstraZeneca continues to trade at discount to peers GlaxoSmithKline and Shire https://www.proactiveinvestors.co.uk/companies/news/8212/astrazeneca-continues-to-trade-at-discount-to-peers-glaxosmithkline-and-shire-10403.html AstraZeneca’s shares currently trade at about 7.7x forecast earnings for 2010, which compares to a multiple of 10.3x for GlaxoSmithKline and 17.2x for Shire.

]]>
Fri, 20 Nov 2009 07:25:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/8212/astrazeneca-continues-to-trade-at-discount-to-peers-glaxosmithkline-and-shire-10403.html
AstraZeneca Applies To the FDA For Its New Angina and Heart Attack Treatment https://www.proactiveinvestors.co.uk/companies/news/8161/astrazeneca-applies-to-the-fda-for-its-new-angina-and-heart-attack-treatment-10346.html Thu, 19 Nov 2009 07:03:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/8161/astrazeneca-applies-to-the-fda-for-its-new-angina-and-heart-attack-treatment-10346.html AstraZeneca enters licensing agreement with Nektar Therapeutics https://www.proactiveinvestors.co.uk/companies/news/6386/astrazeneca-enters-licensing-agreement-with-nektar-therapeutics-8363.html Mon, 21 Sep 2009 13:06:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/6386/astrazeneca-enters-licensing-agreement-with-nektar-therapeutics-8363.html AstraZeneca’s IRESSA cancer drug gets EU marketing approval https://www.proactiveinvestors.co.uk/companies/news/4697/astrazenecas-iressa-cancer-drug-gets-eu-marketing-approval-6416.html Wed, 01 Jul 2009 07:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/4697/astrazenecas-iressa-cancer-drug-gets-eu-marketing-approval-6416.html AstraZeneca and Bristol-Myers Squibb diabetes drug gets positive opinion from EU body https://www.proactiveinvestors.co.uk/companies/news/4633/astrazeneca-and-bristol-myers-squibb-diabetes-drug-gets-positive-opinion-from-eu-body-6338.html Fri, 26 Jun 2009 07:37:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/4633/astrazeneca-and-bristol-myers-squibb-diabetes-drug-gets-positive-opinion-from-eu-body-6338.html AstraZeneca wins court order to temporarily stop Apotex launch of generic Pulmicort https://www.proactiveinvestors.co.uk/companies/news/3706/astrazeneca-wins-court-order-to-temporarily-stop-apotex-launch-of-generic-pulmicort-5235.html Fri, 17 Apr 2009 07:28:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/3706/astrazeneca-wins-court-order-to-temporarily-stop-apotex-launch-of-generic-pulmicort-5235.html FDA panel deems AstraZeneca’s Seroquel effective as depression and anxiety treatment, but safety still an issue https://www.proactiveinvestors.co.uk/companies/news/3638/fda-panel-deems-astrazenecas-seroquel-effective-as-depression-and-anxiety-treatment-but-safety-still-an-issue--5156.html Thu, 09 Apr 2009 08:17:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/3638/fda-panel-deems-astrazenecas-seroquel-effective-as-depression-and-anxiety-treatment-but-safety-still-an-issue--5156.html AstraZeneca says US FDA approves asthma drug Symbicort as COPD treatment https://www.proactiveinvestors.co.uk/companies/news/3210/astrazeneca-says-us-fda-approves-asthma-drug-symbicort-as-copd-treatment-4600.html Mon, 02 Mar 2009 09:14:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/3210/astrazeneca-says-us-fda-approves-asthma-drug-symbicort-as-copd-treatment-4600.html AstraZeneca says children’s asthma drug fails clinical trial https://www.proactiveinvestors.co.uk/companies/news/3156/astrazeneca-says-childrens-asthma-drug-fails-clinical-trial-4537.html Tue, 24 Feb 2009 08:54:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/3156/astrazeneca-says-childrens-asthma-drug-fails-clinical-trial-4537.html AstraZeneca secures victory in patent dispute against Teva Pharmaceutical https://www.proactiveinvestors.co.uk/companies/news/1989/astrazeneca-secures-victory-in-patent-dispute-against-teva-pharmaceutical--3039.html Wed, 24 Sep 2008 11:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/1989/astrazeneca-secures-victory-in-patent-dispute-against-teva-pharmaceutical--3039.html